IMS Community Webinar Series: Optimizing the use of ADCs and TCRTs
June 24 - August 26, 2026 - Webinar Series
Are you a community physician treating patients with multiple myeloma?
If so, this workshop is for you!
Because of the limited experience with T cell redirection treatment strategies in the real world and especially bispecific T cell engagers and CAR T therapies among oncologists and health care professionals outside CAR T administering centers, there is a gap in the understanding, management and utilization of these therapies in patients that might benefit from these types of treatments. As more drug products become available through commercial and research routes, there will be a greater need for a close partnership between the centers where these treatments are administered and the smaller community centers where the vast majority of oncology patients are typically followed and receive the bulk of their treatments. There is an urgent need to bridge this knowledge gap and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engagers and CAR T therapies among health care professionals.
Mark your calendars for the 23rd IMS Annual Meeting in Glasgow, Scotland.
The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical, and clinical aspects. This year’s program includes:
Four thematic sessions:
Newly Diagnosed Multiple Myeloma
How to Treat First Relapse
Blood-Based Technology for Diagnosis and Monitoring
Monitoring Immune System and Preventing Infections and Adverse Effects
Talks and symposia led by key opinion leaders in the myeloma community
Keynote addresses
Joint sessions with regulatory agencies and other organizations
Learn about the IMS and Paula and Rodger Riney Foundation Translational Research Award
Learn about the IMS Career Development Award
Meet the recipients of the IMS Translational Research Award!
Meet the recipients of the IMS Career Development Award!
About Our Publications
As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
